Colleen F. Reitan
CIK: 0001740730
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (25 total)
- Jun 4, 2026MYGN
MYRIAD GENETICS INC
Award(A)Direct59.7K shares- - May 20, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Award(A)Direct671 shares- - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct25 shares at avg. $480.98$12K - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct1.5K shares at avg. $478.67$694K - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct1.4K shares at avg. $479.55$665K - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Exercise(M)Direct18K shares at avg. $100.65$1.8M - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct1.6K shares at avg. $457.44$752K - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct1.9K shares at avg. $458.86$866K - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct1.4K shares at avg. $459.73$645K - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct473 shares at avg. $460.71$218K - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct2.3K shares at avg. $461.92$1.1M - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct1.7K shares at avg. $463.00$765K - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct799 shares at avg. $464.36$371K - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct222 shares at avg. $471.25$105K - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct823 shares at avg. $472.82$389K - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct838 shares at avg. $474.22$397K - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct951 shares at avg. $474.85$452K - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct972 shares at avg. $476.31$463K - Sep 9, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct1.2K shares at avg. $477.47$565K - Jun 5, 2025MYGN
MYRIAD GENETICS INC
Award(A)Direct49.8K shares- - May 8, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Award(A)Direct775 shares- - Apr 16, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct36 shares at avg. $232.86$8K - Oct 17, 2024ALNY
ALNYLAM PHARMACEUTICALS, INC.
Purchase(P)Direct4 shares at avg. $302.67$1K - Sep 3, 2024MYGN
MYRIAD GENETICS INC
Sale(S)Direct46K shares at avg. $27.95$1.3M - Aug 29, 2024ALNY
ALNYLAM PHARMACEUTICALS, INC.
Purchase(P)Direct32 shares at avg. $286.00$9K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 4, 2026 |  MYGN MYRIAD GENETICS INC | Award(A) | 59,701 | - | $0 | Direct |
| May 20, 2026 |  ALNY ALNYLAM PHARMACEUTICALS, INC. | Award(A) | 671 | - | $0 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 25 | $480.98 | $12,025 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 1,450 | $478.67 | $694,072 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 1,386 | $479.55 | $664,656 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Exercise(M) | 18,000 | $100.65 | $1,811,700 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 1,645 | $457.44 | $752,489 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 1,888 | $458.86 | $866,328 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 1,403 | $459.73 | $645,001 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 473 | $460.71 | $217,916 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 2,290 | $461.92 | $1,057,797 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 1,652 | $463.00 | $764,876 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 799 | $464.36 | $371,024 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 222 | $471.25 | $104,618 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 823 | $472.82 | $389,131 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 838 | $474.22 | $397,396 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 951 | $474.85 | $451,582 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 972 | $476.31 | $462,973 | Direct |
| Sep 9, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 1,183 | $477.47 | $564,847 | Direct |
| Jun 5, 2025 | MYGN MYRIAD GENETICS INC | Award(A) | 49,796 | - | - | Direct |
| May 8, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Award(A) | 775 | - | - | Direct |
| Apr 16, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 36 | $232.86 | $8,383 | Direct |
| Oct 17, 2024 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Purchase(P) | 4 | $302.67 | $1,211 | Direct |
| Sep 3, 2024 | MYGN MYRIAD GENETICS INC | Sale(S) | 46,012 | $27.95 | $1,285,851 | Direct |
| Aug 29, 2024 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Purchase(P) | 32 | $286.00 | $9,152 | Direct |
1-25 of 25 transactions
About Reitan Colleen F
Reitan Colleen F (SEC CIK 0001740730) files insider reports with the SEC as Director of MYRIAD GENETICS INC (MYGN) and Director of ALNYLAM PHARMACEUTICALS, INC. (ALNY).
Signal8 holds 6 ownership filings by Reitan Colleen F, all Form 4s, filed between Sep 4, 2024 and Jun 5, 2026. Those filings report 25 transactions, from Aug 29, 2024 to Jun 4, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Reitan Colleen F's filings is in SALT LAKE CITY, UT.
Recent filings by Reitan Colleen F
- Jun 4, 2026: Grant or award of MYGN shares (Form 4, code A).
- May 20, 2026: Grant or award of ALNY shares (Form 4, code A).
- Sep 9, 2025: Open-market sales of ALNY shares (3 lines, Form 4, code S).
- Sep 9, 2025: Option exercise of ALNY shares (Form 4, code M).
- Sep 9, 2025: Open-market sales of ALNY shares (13 lines, Form 4, code S).
Other insiders filing for MYRIAD GENETICS INC (MYGN)
- Fox Jennifer Lynne, Chief Legal & Corp Strategy
- Wheeler Benjamin Richard, Chief Financial Officer
- Donnelly Brian J, Chief Commercial Officer
- Sikri Vishal, EVP, Commercial
- Skovronsky Daniel, Director
- Raha Samraat S., President and CEO